No evidence of BRCA2 mutations in chromosome 13q-linked Utah high-risk prostate cancer pedigrees
© Allen-Brady et al; licensee BioMed Central Ltd. 2009
Received: 03 April 2009
Accepted: 28 May 2009
Published: 28 May 2009
Skip to main content
© Allen-Brady et al; licensee BioMed Central Ltd. 2009
Received: 03 April 2009
Accepted: 28 May 2009
Published: 28 May 2009
Germline mutations in the BRCA2 gene have been suggested to account for about 5% of familial prostate cancer; mutations have been reported in 2% of early onset (i.e., ≤ 55 years) prostate cancer cases and a segregating founder mutation has been identified in Iceland (999del5). However, the role of BRCA2 in high risk prostate cancer pedigrees remains unclear.
We examined the potential involvement of BRCA2 in a set offive high-risk prostate cancer pedigrees in which all prostate cases were no more distantly related than two meioses from another case, and the resulting cluster contained at least four prostate cancer cases. We selected these five pedigrees from a larger dataset of 59 high-risk prostate cancer pedigrees analyzed in a genome-wide linkage screen. Selected pedigrees showed at least nominal linkage evidence to the BRCA2 region on chromosome 13q. We mutation screened all coding regions and intron/exon boundaries of the BRCA2 gene in the youngest prostate cancer case who carried the linked 13q segregating haplotype, as well as in a distantly related haplotype carrier to confirm any segregation. We observed no known protein truncating BRCA2 deleterious mutations. We identified one non-segregating BRCA2 variant of uncertain significance, one non-segregating intronic variant not previously reported, and a number of polymorphisms.
In this set of high-risk prostate cancer pedigrees with at least nominal linkage evidence to BRCA2, we saw no evidence for segregating BRCA2 protein truncating mutations in heritable prostate cancer.
Prostate cancer is the most frequently diagnosed cancer, excluding basal and squamous cell skin cancers, and the second leading cause of cancer death in men in the United States. Significant familial clustering of prostate cancer cases has been observed [1, 2] suggesting that highly penetrant prostate cancer predisposition genes exist. Although a number of genes have been implicated in prostate cancer (see Review articles [2–4]), most require validation and functional studies to determine their precise role in the etiology of prostate cancer.
One gene that has consistently been associated with prostate cancer is BRCA2 (see Review article). Early studies in Iceland identified a BRCA2 founder mutation, 999del5, that segregates with prostate cancer particularly in cases diagnosed ≤ 65 years. [6, 7] The Breast Cancer Linkage Consortium has reported an increased risk of prostate cancer in families with any known deleterious BRCA2 mutation First-degree male relatives of women with breast and/or ovarian cancer and a known BRCA2 mutation were found to have an increased risk of prostate cancer (RR = 4.65), and rates were found to be even higher in male relatives less than 65 years of age (RR = 7.33) However, a subsequent study of 22 families with a minimum of three men affected with prostate cancer that also included at least two cases of breast and/or ovarian cancer observed no BRCA2 truncating mutations Another common BRCA2 founder mutation, 6174delT, has been found to increase prostate cancer risk in some individuals with Ashkenazi Jewish ancestry, but these results have not been confirmed in other studies [11–14]
It has been estimated that germline mutations in BRCA2 account for about 5% of prostate cancer in familial clusters[15, 16] However, other than the founder mutation in Iceland and possibly another mutation in those with Ashkenazi Jewish ancestry, the role of segregating BRCA2 mutations in familial prostate cancer remains unclear. To further assess involvement of BRCA2 in familial prostate cancer, we screened for BRCA2 variants in high-risk prostate cancer pedigrees that showed at least nominal linkage to the BRCA2 region on chromosome 13q.
The vast majority of studied Utah high-risk prostate cancer families have been identified using the Utah Population Database (UPDB) The UPDB is a computerized database that links cancer information from the Utah Cancer Registry (UCR) to genealogy information for almost four million individuals who are, for the most part, descendants of the nineteenth century pioneers to Utah. The UCR began collecting statewide cancer records in 1966, and in 1973 the UCR became part of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. As a SEER site, all cancers in the state of Utah, except basal and squamous cell skin cancers, are required by law to be reported. Approximately 60% of cancer records in the UCR link to a UPDB genealogy record. The Utah population represented in the UPDB have been shown to be similar to other Caucasian populations of Northern and Western European descent  with normal levels of inbreeding On rare occasions, families with an excess of prostate cancer who reside outside of Utah are contributed to the Utah Prostate Cancer High-Risk Pedigree Resource by collaborators.
From the Utah High-Risk Prostate Cancer Pedigree Resource of over 300 sampled pedigrees, we selected a subset of the most informative prostate cancer pedigrees for a genome-wide linkage search.  These pedigrees satisfied the following two criteria: all cases were no more distantly related than two meioses from another case and the resulting cluster contained at least four cases. There were no other exclusion criteria for the linkage analysis including age at diagnosis, or other cancers or disease states (e.g., breast cancer) within the family. We did not remove any prostate cancer pedigrees from our High-Risk Prostate Cancer Resource because of prior knowledge of a BRCA2 mutation. We note that our high-risk prostate cancer pedigree definition is more strict than the usual definition of a high-risk prostate cancer pedigree We identified 59 pedigrees, from 3 to 6 generations in size, containing 464 cases and an additional 1,261 unaffected relatives. We genotyped 246 of the 464 cases, as well as 640 of the 1,261 unaffected relatives to infer genotypes of deceased relatives or phase for genotyped cases. All enrolled subjects gave informed consent, and this study was approved by the University of Utah Institutional Review Board.
Genotyping was performed by the Center for Inherited Disease Research (CIDR) using a panel of 404 fluorescent microsatellite (STR) markers spaced ~10 cM apart across the genome. The laboratory methods used by CIDR are described in detail at http://www.cidr.jhmi.edu. Mendelian inheritance was verified for all markers, and samples with an inheritance incompatibility were set to missing.
Linkage analysis was performed using MCLINK,  a Markov chain Monte-Carlo method that allows for fully informative multilocus linkage analysis on large extended pedigrees, using the Smith et al. prostate cancer inheritance model.  MCLINK computes the robust multipoint linkage statistic proposed by Göring and Terwilliger,  referred to as theta LOD or TLOD The results of this genome-wide linkage scan are reported elsewhere. 
Characteristics of five high-risk prostate cancer pedigrees showing linkage evidence to chromosome 13q, BRCA2 region1
Max TLOD score on chr 13q
Location of max TLOD on chr 13
# prostate cancer cases in pedigree (genotyped)
# prostate cancer cases carrying segregating 13q haplotype3
Age at prostate cancer diagnosis (yrs)
57, 59, 61, 61, 64, 73, 74, 84, 87
60, 60, 78, 79, 82
59, 61, 62, 65, 66, 66, 70, 73, 77, 78
52, 59, 59, 63, 63, 69, 72, 74, 75, 76, 80, 85
54, 57, 62, 64, 67, 82
In each linked pedigree, we selected the youngest prostate cancer case that carried a segregating haplotype of interest as well as the most distantly related individual in the pedigree who also carried the same segregating haplotype for BRCA2 mutation screening. One pedigree had two 13q segregating haplotypes; both were screened for mutations. Hence, twelve individuals were selected for BRCA2 mutation screening. Ten of the subjects for mutation screening were prostate cancer cases and two of the subjects were unaffected relatives (1 male and 1 female) who carried the 13q segregating haplotype.
All coding regions and intron/exon boundaries of the BRCA2 gene were screened for mutations using 47 primer pairs that have been described previously.  Shorter exons were amplified in a single fragment and longer exons were amplified as sub fragments. There were five fragments for exon 10, 16 fragments for exon 11, and two fragments for each of the following exons: 14, 18, and 27. PCR reactions were performed in a reaction volume of 10 μl containing 5 ng of genomic DNA, 1 mM dNTPs, 1.5 mM or 2.5 mM MgCl2, 1 μM of both the forward and reverse primer, and 0.25 U Amplitaq DNA polymerase (Applied Biosystems, Foster City CA).
PCR products were cleaned using the ExoSAP-IT method (USB Corporation, Cleveland, OH). DNA sequencing reactions were conducted using BigDye® Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems, Foster City CA) and sequence data were obtained on both forward and reverse PCR primers on ABI 3730xl Genetic Analyzer (Applied Biosystems, Foster City CA). Contigs were assembled using PhredPhrap/Consed Polymorphisms were detected using Polyphred  and MutationSurveyor  by two independent researchers. All variants were unanimously confirmed.
Summary characteristics of the five screened pedigrees are shown in Table 1. In four of the five pedigrees, the linked 13q segregating haplotype was carried by the majority of prostate cancer cases. The age at diagnosis varied from what would be considered an early-onset case (i.e., ≤ 55 years – two prostate cancer cases), to cases with a diagnosis over the age of 80 years (six cases).
Risk of BRCA2 associated cancers in descendants of most distant ancestor carrying the 13q haplotype1
# of observed cancers
# of expected cancers
BRCA2 variants of unknown significance observed in Utah high-risk prostate cancer pedigrees
Amino Acid change
Desc. On BIC1
No. found in prostate cases
/no. with valid results2
BRCA2 polymorphisms observed in Utah high-risk prostate cancer pedigrees
Amino Acid change
# found in prostate cases
/# with valid results2
Literature observing same variant in other prostate cancer cases
Our results are consistent with a growing pool of evidence that BRCA2 plays at most a minor role in causing prostate cancer in high-risk prostate cancer families. As with our results, Sinclair et al.  using high-risk prostate cancer pedigrees found no BRCA2 truncating mutations, but found one previously reported missense mutation and two previously unreported intronic polymorphisms. Gayther et al.  found two germ-line BRCA2 truncating mutations in 38 high-risk, familial prostate cancer pedigree in two individuals diagnosed ≤ 56 years, neither of which was found to segregate. A recent study by Agalliu et al. using 266 subjects in high-risk prostate cancer families also reported no disease-associated protein truncating BRCA2 mutations Our study is unique in that we focused on pedigrees with strong linkage evidence near the BRCA2 gene region on chromosome 13q, and that all pedigrees met a very strict definition of high-risk.
While the five linked pedigrees studied here appear to have minimal involvement of the most likely candidate gene in the region (i.e., BRCA2), there is still unexplained linkage evidence on chromosome 13q that cannot be attributable to BRCA2 coding mutations. There may be yet unidentified regulatory BRCA2 mutations, deletions, and/or rearrangements that were not screened as part of this study. Alternatively, the nominal linkage evidence in these prostate cancer pedigrees may represent other prostate cancer predisposition genes located near BRCA2 including HMG1, LGR8, CCNA1, TRPC4, and FOXO1. Finally, the results may be spurious as only a limited number of pedigrees (i.e., five of the original 59 pedigrees) were studied, and segregation analysis with chromosome 13q may not be the most reliable way of identifying BRCA2 mutation families.
This study adds further evidence that BRCA2 has a limited role in heritable prostate cancer. We observed no evidence for BRCA2 coding mutations segregating within our Utah high-risk prostate cancer pedigrees with prior linkage evidence to chromosome 13q.
ovarian-cancer cluster region
Utah Population Database
Utah Cancer Registry
National Cancer Institute's Surveillance, Epidemiology, and End Results Program
Center for Inherited Disease Research
short tandem repeat/microsatellite marker
Breast Cancer Information Core
The authors wish to thank G. Bryce Christensen for his statistical analysis help and Kim Nguyen for his help in the laboratory. Data collection for this publication was supported by: the NIH National Cancer Institute grant R01 CA90752 (to L.A. Cannon-Albright), a subcontract from Johns Hopkins University with funds provided by grant R01 CA89600 from the NIH National Cancer Institute (to L.A. Cannon-Albright), and the National Institutes of Health grant K07 CA98364 (to N.J. Camp). Research was supported by the Utah Cancer Registry, which is funded by Contract #N01-PC-35141 from the National Cancer Institute's SEER Program with additional support from the Utah State Department of Heath and the University of Utah. Partial support for all datasets within the Utah Population Database (UPDB) was provided by the University of Utah Huntsman Cancer Institute. Partial support for some high risk pedigree sampling was provided by Myriad Genetics. Additional support was obtained from the Public Health Services research grant number M01-RR00064 from the National Center for Research Resources. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number N01-HG-65403. Mutation screening was supported by the Intramural Program of the National Human Genome Research Institute.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.